LFCM
ADAP
Long Focus Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.69M | Hold |
23,756,687
| – | – | 0.22% | 61 |
|
|
2025
Q1 | $4.68M | Buy |
23,756,687
+3,262,294
| +16% | +$643K | 0.16% | 62 |
|
|
2024
Q4 | $11M | Buy |
20,494,393
+7,194,503
| +54% | +$3.88M | 0.36% | 36 |
|
|
2024
Q3 | $12.6M | Buy |
13,299,890
+953,473
| +8% | +$906K | 0.44% | 30 |
|
|
2024
Q2 | $12M | Buy |
12,346,417
+1,662,184
| +16% | +$1.62M | 0.46% | 27 |
|
|
2024
Q1 | $16.9M | Sell |
10,684,233
-1,402,682
| -12% | -$2.22M | 0.86% | 16 |
|
|
2023
Q4 | $9.58M | Buy |
12,086,915
+1,123,757
| +10% | +$891K | 0.32% | 31 |
|
|
2023
Q3 | $8.55M | Buy |
10,963,158
+3,150,630
| +40% | +$2.46M | 0.31% | 28 |
|
|
2023
Q2 | $7.23M | Buy |
7,812,528
+2,377,089
| +44% | +$2.2M | 0.33% | 37 |
|
|
2023
Q1 | $5.92M | Buy |
5,435,439
+151,800
| +3% | +$165K | 0.34% | 39 |
|
|
2022
Q4 | $7.71M | Buy |
5,283,639
+494,149
| +10% | +$721K | 0.53% | 33 |
|
|
2022
Q3 | $5.15M | Buy |
4,789,490
+109,999
| +2% | +$118K | 0.5% | 36 |
|
|
2022
Q2 | $7.96M | Buy |
4,679,491
+250,000
| +6% | +$425K | 0.83% | 18 |
|
|
2022
Q1 | $9.13M | Buy |
4,429,491
+2,267,178
| +105% | +$4.67M | 1.17% | 18 |
|
|
2021
Q4 | $8.11M | Buy |
+2,162,313
| New | +$8.11M | 1.07% | 13 |
|